PHAXIAM is a clinical-stage biopharmaceutical company developing innovative bacteriophage-based therapies to fight severe resistant infections.

PHAXIAM leverages an innovative approach based on the use of phages, natural viruses that specifically target and kill bacteria. This targeted mechanism offers an effective solution to combat resistant bacterial infections.

PHAXIAM is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, responsible for more than two-thirds of hospital-acquired resistant infections: Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.